MR-guided focused ultrasound to be evaluated within the Orderly introduction framework in Sweden

On May 6, 2024, the Swedish Medical Technologies Product (MTP) Council commissioned the Dental and Pharmaceutical Benefits Agency (TLV) to perform a health economic evaluation of MR-guided focused ultrasound (MRgFUS) for the treatment of patients with essential tremor and Parkinson's disease as part of the Orderly introduction framework. This framework supports the national adoption of novel technologies via a staged process, including horizon scanning, selection of the method for evaluation, the decision on national collaboration, health economic evaluation by the TLV, and recommendations by the MTP Council to regions regarding the implementation of the technology and criteria for use.

The MRgFUS device considered for the current evaluation is Exablate Neuro. MTP Council mentions that Exablate Neuro is not currently available in Sweden. In case of insufficient control of tremors with pharmacotherapy, patients with essential tremors or Parkinson's disease are offered deep brain stimulation (DBS), which is invasive and not suitable for everyone. Exablate Neuro can be an alternative to DBS. This is supported by the results of a recent regional HTA report (HTA Skåne).

See the full details in Swedish here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.